Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, Aorite, and others [1]. Core Views - The pharmaceutical sector experienced a 3.29% increase this week, outperforming the CSI 300 index by 4.37 percentage points. Sub-sectors such as pharmaceutical commerce, pharmacies, and innovative drugs performed well, while medical devices and consumables lagged [2][12]. - The report emphasizes the importance of market pricing power and the impact of liquidity and risk appetite on investment strategies, particularly in innovative drugs and related supply chains [2][12]. - The report highlights the upcoming patent expirations for small molecule drugs, which are expected to create significant demand for raw materials, with a projected sales impact of $390 billion from 2025 to 2030 [3][13]. Summary by Sections Industry Performance - The pharmaceutical sector's performance this week was characterized by a 3.29% increase, with notable performances in pharmaceutical commerce (+7.31%), pharmacies (+6.83%), and innovative drugs (+5.01%). In contrast, medical devices (0.16%) and new medical infrastructure (1.18%) showed weaker performance [17][29]. - The overall price-to-earnings (P/E) ratio for the pharmaceutical industry is reported at 30.84 times, with a premium of 25.08% compared to the overall A-share market excluding the financial sector [33]. Company Dynamics - Notable company announcements include: - Prologis Pharmaceuticals received a European certificate for its product, enhancing its international market prospects [18]. - Jianyou Co. announced FDA approval for its production site, expanding its manufacturing capabilities [19]. - Fuyuan Pharmaceuticals received a drug registration certificate from the National Medical Products Administration, allowing for the marketing of its product [20]. - The report suggests focusing on companies benefiting from domestic innovative drug support policies, such as Yangguang Nuohuo and Nuosige, as well as those with strong overseas business prospects [15][7]. Raw Materials - The report indicates that the raw materials sector is expected to see a significant increase in demand due to patent expirations, with a projected sales impact of $390 billion from 2025 to 2030. The production of raw materials in H1 2025 reached 1.935 million tons, reflecting an 8.2% year-on-year increase [3][13]. - Companies recommended for attention in the raw materials sector include Aorite, Prologis Pharmaceuticals, and Aoxiang Pharmaceuticals, focusing on innovation and strong performance [3][16].

Core Insights - Tonghua Pharmaceutical announced the receipt of two invention patents from the National Intellectual Property Administration, focusing on a regeneration method for phase change deactivated ruthenium carbon catalysts and a preparation method and application for carbon catalytic materials co-doped with single and multi-atom transition metals [1] Group 1 - The company received an invention patent for a regeneration method of phase change deactivated ruthenium carbon catalysts [1] - The second patent pertains to a method for preparing and applying carbon catalytic materials co-doped with single and multi-atom transition metals [1]

证券代码：300636 证券简称：同和药业 公告编号：2025-059 江西同和药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的发明专利证书，具体情况如下： 1、发明名称：一种相变化失活钌碳催化剂的再生方法 专利号：ZL 2022 1 1259276.2 专利类型：发明专利 专利申请日：2022.10.14 授权公告日：2025.11.14 注：专利权自授权公告之日起生效。专利权期限为二十年，自申请日起算。 本次两个发明专利是由公司和台州学院共同研发的催化剂技术 专利。 发明1涉及一种相变化失活钌碳催化剂的再生方法。该种再生方 法一方面增加了碳材料的活性位点；另一方面将大颗粒钌金属变为钌 晶粒，从而提高了再生钌碳催化剂的催化活性。 发明2涉及一种单原子和多原子过渡金属共掺杂碳催化的制备方 专利权人：江西同和药业股份有限公司；台州学院 2、发明名称：一种单原子和多原子过渡金属共掺杂碳催化材料 及其制备方法和应用 专利号：ZL 2022 1 1 ...

上海市通力律师事务所 关于江西同和药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致: 江西同和药业股份有限公司 上海市通力律师事务所(以下简称"本所")接受江西同和药业股份有限公司(以下简称 "公司")的委托, 指派本所蔡丛丛律师、俞挺律师(以下简称"本所律师")根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范性 文件(以下统称"法律法规")及《江西同和药业股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第一次临时股东大会(以下简称"本次股东大会")相关事宜出具法律 意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有 签署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和 有效的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见 ...

江西同和药业股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300636 证券简称：同和药业 公告编号：2025-058 余绍炯先生符合《公司法》等相关法律法规、规范性文件及《公 司章程》有关董事任职的资格和条件，其当选职工代表董事后，公司 第四届董事会中兼任公司高级管理人员以及由职工代表担任的董事 人数总计不超过公司董事总数的二分之一，符合相关法律法规的规定。 一、非独立董事辞职情况 江西同和药业股份有限公司（以下简称"公司"）董事会近日收 到非独立董事蒋元森先生递交的书面辞职报告，因公司治理结构调整， 蒋元森先生向董事会申请辞去公司第四届董事会非独立董事、第四届 董事会战略委员会委员、第四届董事会提名委员会委员职务。辞去董 事职务后，蒋元森先生将继续担任公司副总经理职务。蒋元森先生的 原定任期至公司第四届董事会届满之日，其辞职不会导致公司董事会 人数低于法定最低人数，不会影响公司董事会的正常运行，辞职报告 自送达董事会之日起生效。 截止本公告披露日，蒋元森先生不存在应当履行而未履行的承诺 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-057 江西同和药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 本次股东大会由公司董事会召集，董事长庞正伟先生主持。会议 采用现场投票和网络投票相结合的表决方式进行表决。会议的召集、 召开、表决程序符合《中华人民共和国公司法》、《中华人民共和国证 券法》等法律、法规及规范性文件和公司章程的规定。 （二）出席会议的股东、股东代表及其持有股份情况： 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无否决议案的情形。 2.本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、股东大会召开的时间：2025 年 11 月 11 日 2、股东大会的召开地点：江西省奉新县江西奉新高新技术产业 园区公司会议室 3、是否符合有关法律法规和公司章程的规定： 1、股东出席的总体情况： 通过现场和网络投票的股东 66 人，代表股份 131,891,160 股， 占公司有表决权股份总数的 31.4063％。 其中：通过现场投票的股东 14 人， ...

Core Viewpoint - The company, Tonghua Pharmaceutical (300636.SZ), has successfully passed the cGMP inspection conducted by the U.S. FDA, confirming compliance with U.S. drug production quality management standards [1] Group 1: Inspection Details - The cGMP inspection took place from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls [1] - The company received confirmation from the U.S. FDA's official website that it has met the cGMP management standards [1]

Core Viewpoint - The company, Tonghe Pharmaceutical, has successfully passed the cGMP inspection by the FDA, indicating compliance with U.S. drug production quality standards [1] Group 1: FDA Inspection - The company underwent an FDA cGMP inspection from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls [1] - The company has received confirmation from the FDA's official website that it has passed the inspection [1]

Core Viewpoint - The company successfully passed the FDA's cGMP inspection, which is a significant achievement reflecting its adherence to high international quality management standards and enhancing its prospects in the U.S. and international markets [1] Group 1: FDA Inspection - The company underwent an FDA cGMP inspection from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls [1] - The company achieved a zero-defect result in the FDA inspection, indicating full compliance with cGMP regulations [1] Group 2: Implications - The successful inspection is a strong affirmation of the effective operation of the company's management system [1] - This accomplishment is expected to positively impact the company's ability to expand into the U.S. market and other international markets [1]

证券代码：300636 证券简称：同和药业 公告编号：2025-056 江西同和药业股份有限公司 关于通过美国 FDA 现场检查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于 2025 年 8 月 4 日至 2025 年 8 月 7 日接受了美国食品药品监督管理局（以下简称 "美国 FDA"）的 cGMP（现行药品生产质量管理规范）现场检查，检 查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室 控制六大系统。 近日，公司从美国 FDA 官网（https://datadashboard.fda.gov /oii/cd/inspections.htm)获悉公司已通过了上述现场检查，符合美 国 FDA 的 cGMP 管理规范。 一、 FDA 现场检查的相关信息 1、企业名称：江西同和药业股份有限公司 2、企业地址：江西省奉新高新技术产业园区 3、检查时间：2025 年 8 月 4 日-2025 年 8 月 7 日 4、检查范围：公司一厂区涉及原料药产品（加巴喷丁、塞来昔 布等）的生产制造 5、FDA ...